LINC Conference 2025 - 30 day results of the PATCH study suggests the PerQSeal vascular closure device (Vivasure Medical Limited) can be used as an alternative percutaneous procedure for large-bore common femoral access, showing low risk of haematoma and a medium time of 0 minutes to achieve vessel closure.

Dr Sean Lyden (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the PATCH single-arm, perspective study (NCT05653336) investigating the safety and effectiveness of the PerQseal vascular closure device using 14-22F sheaths for large-bore common femoral access. Patients receiving transcatheter aortic valve repair, thoracic endovascular aortic repair, and endovascular aneurysm repair from the US and Europe were enrolled in the study. The primary safety endpoint was the rate of major access site complications, and the primary effectiveness endpoint was time to hemostasis.

Interview Questions:
1. What is the reasoning behind the PATCH study?
2. Could you tell us about the unique features of the PerQSeal vascular closure device?
3. What was the study design and patient population?
4. What are your key findings?
5. How should these findings impact clinical practice?
6. What further study is needed in this area?

Recorded remotely from Ohio, 2025

Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh, Dan Brent

Support: This is an independent interview produced by Radcliffe Vascular.